Serum Institute Of India Corona Vaccine
- All
- News
- Videos
-
From May 1, Pay More For Second Jab Of Covishield
COVID-19 vaccine: From May 1, 2021, a jab of Serum Institute of India's Covishield vaccine will cost Rs 600 in private hospitals.
-
Vaccine Questions Answered As India Set For First Covid Shots
Ahead of the launch of Covid vaccination on Saturday, the Centre has circulated a factsheet with information on the two vaccines -- Covishield and Covaxin -- that will be used in what officials describe as the 'world's biggest' such exercise. Around 30 crore people will be vaccinated in the next few months during the nationwide drive.
-
Serum Institute Expects WHO Emergency Approval For Astrazeneca Shot Soon
The Serum Institute of India expects WHO emergency-use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for mid and low income countries, its chief executive said.
-
Assam First To Get Both Covid Vaccines, Storage Ready For 3 Crore Doses
Assam became the first state in the northeast to have received both the coronavirus vaccines -- Covishield and Covaxin -- ahead of the mass inoculation programme set to start January 16.
-
India's Wait Over, Drug Regulator Says Covid Vaccines Cleared "110% Safe"
Two vaccines for coronavirus, Oxford University's Covishield, which is being developed by the Pune-based Serum Institute, and Bharat Biotech's Covaxin, received emergency approval from the country's drug regulator on Sunday. "We'll never approve anything if there is slightest of safety concern. The vaccines are 110 per cent safe," Drug Controller G...
-
Coronavirus Highlights: Oxford COVID-19 Vaccine Covishield Approved For Use In India
India's drugs regulator on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
-
Coronavirus India Highlights: Oxford COVID-19 Vaccine Cleared By Expert Panel For India
The Oxford COVID-19 vaccine manufactured by the Serum Institute of India will be sent for approval to the regulator Drugs Controller General of India (DCGI) by a government-appointed panel of experts, sources have said.
-
Coronavirus India Highlights: Zero Hospitalisation Among Those Who Took Vaccine, Says Serum Institute's Adar Poonawalla
India has reported 41,322 fresh COVID-19 cases till today, 4% lower than on Friday, taking its overall number to 93.51 lakh cases and 1,36,200 deaths, Union Health Ministry data shows. These numbers come even as a vaccine to fight back the virus seemed tantalisingly close. The states of Maharashtra, Karnataka, Andhra Pradesh, Tamil Nadu, and Kerala...
-
Envoys From 100 Countries To Visit Pune On December 4 Amid Vaccine Production
Ambassadors and envoys from 100 countries will visit Serum Institute of India and Gennova Biopharmaceuticals Ltd in Pune on December 4 amid the coronavirus outbreak and race for vaccines to combat the infection, a senior official said on Tuesday.
-
Covishield Vaccine: Phase II Human Trial Of Oxford COVID-19 Vaccine Candidate Begins In Pune
The Phase II human clinical trial of the Oxford COVID-19 vaccine candidate, being manufactured by the Pune-based Serum Institute of India (SII), began at a medical college and hospital in the city today.
-
From May 1, Pay More For Second Jab Of Covishield
COVID-19 vaccine: From May 1, 2021, a jab of Serum Institute of India's Covishield vaccine will cost Rs 600 in private hospitals.
-
Vaccine Questions Answered As India Set For First Covid Shots
Ahead of the launch of Covid vaccination on Saturday, the Centre has circulated a factsheet with information on the two vaccines -- Covishield and Covaxin -- that will be used in what officials describe as the 'world's biggest' such exercise. Around 30 crore people will be vaccinated in the next few months during the nationwide drive.
-
Serum Institute Expects WHO Emergency Approval For Astrazeneca Shot Soon
The Serum Institute of India expects WHO emergency-use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for mid and low income countries, its chief executive said.
-
Assam First To Get Both Covid Vaccines, Storage Ready For 3 Crore Doses
Assam became the first state in the northeast to have received both the coronavirus vaccines -- Covishield and Covaxin -- ahead of the mass inoculation programme set to start January 16.
-
India's Wait Over, Drug Regulator Says Covid Vaccines Cleared "110% Safe"
Two vaccines for coronavirus, Oxford University's Covishield, which is being developed by the Pune-based Serum Institute, and Bharat Biotech's Covaxin, received emergency approval from the country's drug regulator on Sunday. "We'll never approve anything if there is slightest of safety concern. The vaccines are 110 per cent safe," Drug Controller G...
-
Coronavirus Highlights: Oxford COVID-19 Vaccine Covishield Approved For Use In India
India's drugs regulator on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
-
Coronavirus India Highlights: Oxford COVID-19 Vaccine Cleared By Expert Panel For India
The Oxford COVID-19 vaccine manufactured by the Serum Institute of India will be sent for approval to the regulator Drugs Controller General of India (DCGI) by a government-appointed panel of experts, sources have said.
-
Coronavirus India Highlights: Zero Hospitalisation Among Those Who Took Vaccine, Says Serum Institute's Adar Poonawalla
India has reported 41,322 fresh COVID-19 cases till today, 4% lower than on Friday, taking its overall number to 93.51 lakh cases and 1,36,200 deaths, Union Health Ministry data shows. These numbers come even as a vaccine to fight back the virus seemed tantalisingly close. The states of Maharashtra, Karnataka, Andhra Pradesh, Tamil Nadu, and Kerala...
-
Envoys From 100 Countries To Visit Pune On December 4 Amid Vaccine Production
Ambassadors and envoys from 100 countries will visit Serum Institute of India and Gennova Biopharmaceuticals Ltd in Pune on December 4 amid the coronavirus outbreak and race for vaccines to combat the infection, a senior official said on Tuesday.
-
Covishield Vaccine: Phase II Human Trial Of Oxford COVID-19 Vaccine Candidate Begins In Pune
The Phase II human clinical trial of the Oxford COVID-19 vaccine candidate, being manufactured by the Pune-based Serum Institute of India (SII), began at a medical college and hospital in the city today.
